Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061264 | 0.88 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL3049670 | 0.86 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL3048385 | 0.82 | MAPK14 (0.65) | MAPK14 | |
| SCHEMBL3051455 | 0.82 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL3051000 | 0.81 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL3052171 | 0.80 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL3051914 | 0.79 | MAPK14 (0.39) | MAPK14 | |
| SCHEMBL3054268 | 0.79 | ALDH1A1 (0.47) | MAPK14 | |
| SCHEMBL3046073 | 0.78 | NPC1 (0.51) | MAPK14 | |
| SCHEMBL5076262 | 0.77 | MAPK14 (0.40) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | claimed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.